"According to the industry, the vaccine seed already fulfilled the industry standard where the yield matches the industry's demand. It is also immunogenic," PRBME vaccine researcher Tedjo Sasmono disclosed at a BRIN event here on Tuesday.
PRBME is developing the Merah Putih vaccine seed using a recombinant protein platform that utilizes yeast and mammalian cells, he said.
For the platform that utilizes yeast cells, the vaccine cell is already at PT Bio Farma, an industry partner in vaccine development, he added.
"The yeast one has fulfilled the industry's requirement and will be further developed and produced," he elaborated.
The development of a vaccine from the vaccine seed now lies in the hands of the industry, he said adding, the primary part of the vaccine seed research, which was PRBME's job, is already over.
The PRBME is continuing to interact with Bio Farma on developing the vaccine seed into a vaccine, he informed.
PRBME is routinely conducting consultations, discussions, and figuring out the best purification method for vaccine development with PT Bio Farma so that the vaccine can immediately be downstreamed, he said.
Meanwhile, in the case of the vaccine seed developed by utilizing mammalian cells, the industry has deemed that the productivity from the vaccine seed meets the requirement, Sasmono said.
Scientifically, the vaccine seed fulfills the immunogenicity aspect or has the capacity to trigger an immune response, which produces antibodies in the human body, he explained.
However, PRBME has not yet found an industry partner for developing a vaccine from the vaccine seed and is currently negotiating with the industry, Sasmono said.
Related news: Support development of indigenous vaccines: ministry
Related news: Merah Putih Vaccine suitable for booster, regular vaccination: BRIN
Related news: Protocols for clinical trials of Merah Putih vaccine enter final stage
Translator: Martha S, Fadhli Ruhman
Editor: Sri Haryati
Copyright © ANTARA 2021
